Cardiol Therapeutics Inc. (CRDL) Stock Overview
Explore Cardiol Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Cardiol Therapeutics Inc. (CRDL)
Key Financials
Key Financials
Market Cap
138.8M
P/E Ratio
-4.46
EPS (TTM)
$-0.25
ROE
-1.94%
CRDL Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Cardiol Therapeutics Inc. (NASDAQ: CRDL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Cardiol Therapeutics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CRDL on the NASDAQ shows an RSI of 25.99, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $1.02 for the NASDAQ listing.
Key metrics behind Cardiol Therapeutics Inc.'s NASDAQ-traded stock include a P/E ratio of -4.46 and a market capitalization of 138.8M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CRDL on the NASDAQ.